PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
申请人:Shimma Nobuo
公开号:US20100069629A1
公开(公告)日:2010-03-18
A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility.
A compound, or pharmaceutically acceptable salt thereof, represented by formula (I):
[wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R
1
represents a cyclic substituent].
Pyrimidine derivatives as PI3K inhibitor and use thereof
申请人:Chugai Seiyaku Kabushiki Kaisha
公开号:US08022205B2
公开(公告)日:2011-09-20
A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility.
A compound, or pharmaceutically acceptable salt thereof, represented by formula (I):
[wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and R1 represents a cyclic substituent].
Bis-(sulfonylamino) derivatives for use in therapy
申请人:Bylund Johan
公开号:US09145380B2
公开(公告)日:2015-09-29
The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
Bis-(Sulfonylamino) derivatives for use in therapy
申请人:Bylund Johan
公开号:US20100331321A1
公开(公告)日:2010-12-30
The invention provides compounds of formula (I) wherein R
1
,R
3
,L
1
,L
2
,G
1
,G
2
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.